Shots:
- MTEM to receive $70M up front and is also eligible to receive ~$1.3B as development, regulatory and sales milestone along with royalties on future sales
- MTEM will be responsible for research activities to discover next generation ETBs for multiple targets, of which BMS selected the first target. BMS to get an option to obtain an exclusive WW license to develop and commercialize ETBs directed to each selected target
- Following the exercise of the option, BMS would be solely responsible for developing and commercializing the licensed ETBs. The companies will utilize MTEM’s next generation ETB platform for specific oncology targets
Click here to read full press release/ article | Ref: GlobeNewswire | Image: Molecular Templates
The post BMS Collaborate with Molecular Templates to Develop Engineered Toxin Body Therapies for Cancer first appeared on PharmaShots.
